Craft
  • Home
  •  / Deciphera Pharmaceuticals
Deciphera Pharmaceuticals

Deciphera Pharmaceuticals

Patents (US)

11

Aug, 2017

Market Capitalization

$1.1 B

2022-09-19

Deciphera Pharmaceuticals Summary

Company summary

Overview
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. It utilizes its drug discovery platform and designs kinase inhibitors. The pipeline includes ripretinib, vimseltinib, rebastinib, and DCC-3116.
Type
Public
Founded
2003
HQ
Waltham, MA, US | view all locations
Website
https://www.deciphera.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Steven L. Hoerter

    Steven L. Hoerter, President, Chief Executive Officer

  • Daniel L. Flynn

    Daniel L. Flynn, Executive Vice President, Chief Scientific Officer and Founder

  • Jeff Held

    Jeff Held, Senior Vice President, General Counsel

  • Caroline Chevalier

    Caroline Chevalier, Vice President, Human Resources

Operating MetricsView all

Patents (US)

11

Aug, 2017

Patents (Foreign)

47

Aug, 2017

Patent Applications

49

Aug, 2017

LocationsView all

2 locations detected

  • Waltham, MA HQ

    United States

    200 Smith St

  • Lawrence, KS

    United States

    643 Massachusetts St, Suite 200

Deciphera Pharmaceuticals Financials

Summary financials

Net income (Q3, 2017)
($12.0M)
Cash (Q3, 2017)
$82.1M
EBIT (Q3, 2017)
($12.2M)

Footer menu